Technology | Lung Cancer | October 05, 2018

Body Vision Medical Announces Release of LungVision

Platform creates augmented reality to see fluoroscopically invisible lung lesions

Body Vision Medical Announces Release of LungVision

October 5, 2018 — Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its LungVision platform. The platform will be presented at the CHEST conference, Oct. 7-10 in San Antonio, Texas.

"Body Vision provides a great tool that has changed the way we approached peripheral nodules. Its unique technology creates augmented reality with the ability to see fluoroscopically invisible lesions and the pathways under the live fluoro, while tracking a patient breathing," said D. Kyle Hogarth, M.D., FCCP, president of the Society for Advanced Bronchoscopy, associate professor of medicine, director of bronchoscopy at the University of Chicago. "Once the technology has guided us to the lesion, we confirm the lesion's relationship to the airway with radial-EBUS [endobronchial ultrasound]. We then use our off-the-shelf biopsy instruments via the LungVision catheter. The augmented fluoro image, integrated with the radial EBUS images, allows us to obtain tissue samples with continuous real-time confirmation of location. The beauty of it all is how simple and elegant the technology is."

Body Vision CEO Dorian Averbuch said the product targets small pulmonary nodules that, if diagnosed early, can be resected to cure lung cancer. The technology provides step-by-step guidance through planning, navigation and lesion localization during biopsy.

The clinical experience with the LungVision platform will be featured through the following panel presentations during the CHEST conference at San Antonio, TX:

  • Sun. Oct. 7
    • Krish Bhadra, M.D., Novel Augmented Fluoroscopic Imaging Platform Accuracy Assessment during Navigation Bronchoscopy in Simultaneous Comparison with Cone Beam CT and Radial EBUS
    • D. Kyle Hogarth, M.D., FCCP, A Novel Endobrachial Fluoroscopic Navigation and Localization System: a summary of a multi-center LungVision Trial
  • Tue., Oct. 9
    • Patrick E. Whitten, M.D., FCCP, Augmented Endobronchial Fluoroscopic Navigation and Localization System: Integration of Multimodalities and Biopsy Tools to Increase Diagnostic Yield

For more information: www.bodyvisionmedical.com

Related Content

Sectra Providing Centralized Regional Solution for Digital Pathology in the U.K.
News | Digital Pathology | June 14, 2019
Sectra has signed a five-year contract with North Tees and Hartlepool National Health System (NHS) Foundation Trust for...
Medivis SurgicalAR Gets FDA Clearance
Technology | Virtual and Augmented Reality | June 10, 2019
Medivis announced that its augmented reality (AR) technology platform for surgical applications, SurgicalAR, has...
Ann Arbor Startup Launches Augmented Reality MRI Simulator
Technology | Virtual and Augmented Reality | June 04, 2019
SpellBound, an Ann Arbor startup specializing in augmented reality (AR) tools for children in hospitals, has officially...
SIIM and ACR Host Machine Learning Challenge for Pneumothorax Detection and Localization
News | Artificial Intelligence | June 03, 2019
The Society for Imaging Informatics in Medicine (SIIM) and the American College of Radiology (ACR) are collaborating...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Vast Majority of Heavy Smokers Not Screened for Lung Cancer
News | Lung Cancer | May 29, 2019
Out of more than 7 million current and former heavy smokers, only 1.9 percent were screened for lung cancer in 2016...
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
News | Oncology Diagnostics | May 28, 2019
A new clinical study shows that Natera's Signatera test identified colorectal cancer recurrence up to 16.5 months...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...